

| Study design              |                                                                   | National electronic health databases | Clinical records |     |       | Agreement analysis |                 |
|---------------------------|-------------------------------------------------------------------|--------------------------------------|------------------|-----|-------|--------------------|-----------------|
|                           |                                                                   |                                      | No               | Yes | Total | Overall agreement  | Kappa Statistic |
| Eligibility               |                                                                   | No                                   | 23               | 4   | 27    | 96%                | 0.8936          |
|                           |                                                                   | Yes                                  | 0                | 73  | 73    |                    |                 |
|                           |                                                                   | Total                                | 23               | 77  | 100   |                    |                 |
| Primary Safety Outcome    | Nonfatal Serious Adverse Events                                   | No                                   | 58               | 1   | 59    | 93%                | 0.8526          |
|                           |                                                                   | Yes                                  | 6                | 35  | 41    |                    |                 |
|                           |                                                                   | Total                                | 64               | 36  | 100   |                    |                 |
|                           | Potential Serious Adverse Events – Fatal                          | No                                   | 74               | 0   | 74    | 100%               | 1.000           |
|                           |                                                                   | Yes                                  | 0                | 26  | 26    |                    |                 |
|                           |                                                                   | Total                                | 74               | 26  | 100   |                    |                 |
| Secondary Safety Outcomes | Interruption, reduction or substitution of erlotinib or gefitinib | No                                   | 56               | 6   | 62    | 94%                | 0.8764          |
|                           |                                                                   | Yes                                  | 0                | 38  | 38    |                    |                 |
|                           |                                                                   | Total                                | 56               | 44  | 100   |                    |                 |
|                           | Serious adverse drug reactions                                    | No                                   | 87               | 3   | 90    | 97%                | 0.8529          |
|                           |                                                                   | Yes                                  | 0                | 10  | 10    |                    |                 |
|                           |                                                                   | Total                                | 87               | 13  | 100   |                    |                 |
| Primary variable          | High-risk concomitant medicines use                               | No                                   | 24               | 3   | 27    | 95%                | 0.8717          |
|                           |                                                                   | Yes                                  | 2                | 71  | 73    |                    |                 |
|                           |                                                                   | Total                                | 26               | 74  | 100   |                    |                 |
| Secondary variable        | Comorbidity                                                       | No                                   | 16               | 1   | 17    | 93%                | 0.7779          |
|                           |                                                                   | Yes                                  | 6                | 77  | 83    |                    |                 |
|                           |                                                                   | Total                                | 22               | 78  | 100   |                    |                 |